Effect of recombinant human erythropoietin on anticancer drug-induced anaemia

Br J Haematol. 1990 Aug;75(4):463-8. doi: 10.1111/j.1365-2141.1990.tb07783.x.

Abstract

Anaemia was induced in rats with fluorouracil (5-FU) or cisplatin (CDDP) and the mechanisms of anaemia induction were analysed. Furthermore, the therapeutic effects of recombinant human erythropoietin (rHu Epo) on these anticancer drug-induced anaemias were investigated. In 5-FU-induced anaemia, marked serum erythropoietin (Epo) elevation was observed in inverse correlation to blood Hb concentration and Hb concentration rapidly recovered to normal levels. On the other hand, in CDDP-induced anaemia, serum Epo elevation was modest and the lowered Hb concentration persisted longer. Treatment with rHu Epo significantly improved both anticancer drug-induced anaemias but rHu Epo was more effective on CDDP-induced anaemia. These results suggest that rHu Epo might be useful for the therapy of anaemia associated with anticancer chemotherapy.

MeSH terms

  • Anemia / blood
  • Anemia / chemically induced
  • Anemia / drug therapy*
  • Animals
  • Cisplatin / adverse effects
  • Erythropoietin / therapeutic use*
  • Fluorouracil / adverse effects
  • Hemoglobins / analysis
  • Male
  • Rats
  • Rats, Inbred Strains
  • Recombinant Proteins / therapeutic use
  • Time Factors

Substances

  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin
  • Cisplatin
  • Fluorouracil